Natasha Sherrill, APRN
Family · Anchorage, AKNPI 1609380385
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 34.0% of the total. Among family clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$460
- Novo Nordisk$338
- Astellas Pharma US Inc$182
- Lilly USA, LLC$182
- Sumitomo Pharma America, Inc.$134
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,599100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,223 |
| AstraZeneca(2 entities) | 25 | $460 |
| Novo Nordisk | 21 | $338 |
| Astellas Pharma US Inc | 7 | $182 |
| Lilly USA, LLC | 9 | $182 |
| Sumitomo Pharma America, Inc. | 6 | $134 |
| GSK | 8 | $118 |
| Exact Sciences | 5 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $96 |
| Myovant Sciences Inc. | 4 | $92 |
| Pfizer | 5 | $91 |
| Novartis | 4 | $89 |
| Abbott | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Amarin Pharma, Inc. | 2 | $41 |
| Ascendis Pharma Endocrinology Inc | 1 | $31 |
| Johnson & Johnson | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$126
How this compares
$3,599 in reported general payments places this provider in the 90th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $44,306 |
| RybelsusSemaglutide | 15 | $33,181 |
| JardianceEmpagliflozin | 20 | $27,293 |
| TrulicityDulaglutide | 21 | $19,807 |
| MounjaroTirzepatide | 20 | $19,667 |
| FarxigaDapagliflozin Propanediol | 24 | $19,632 |
| XareltoRivaroxaban | 12 | $18,781 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $16,383 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $16,339 |
| EliquisApixaban | 19 | $15,330 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $11,016 |
| Nebivolol Hcl | 44 | $2,772 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $2,695 |
| SynthroidLevothyroxine Sodium | 15 | $1,815 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 11 | $1,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $338 | $77,48741 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $182 | $39,47441 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $118 | $27,35534 claims |
| AstraZenecaFarxiga | $460 | $19,63224 claims |
| Johnson & JohnsonXarelto | $26 | $18,78112 claims |
| MerckJanumet | $12 | $16,38311 claims |
| PfizerEliquis | $91 | $15,33019 claims |
| AbbVieSynthroid | $1,223 | $1,81515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 315 family providers in Alaska.
Other family in Anchorage
- Erica HeagyAnchorage$249K
- Trisha KernodleAnchorage$60K
- Marisha DietersAnchorage$6K
- Christine HooverAnchorage$6K
- Leigh KeeferAnchorage$5K
- Sara GeraciAnchorage$4K
- Christine SaganAnchorage$4K
- Bethany BuchananAnchorage$4K
- Katherine HardyAnchorage$3K
- Andrea BirchAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.